Article Text

Download PDFPDF

Concise report
A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort
  1. Lara Bossini-Castillo1,
  2. Jasper C A Broen2,
  3. Carmen P Simeon3,
  4. Lorenzo Beretta4,
  5. Madelon C Vonk2,
  6. Norberto Ortego-Centeno5,
  7. Gerard Espinosa6,
  8. Patricia Carreira7,
  9. María Teresa Camps8,
  10. Nuria Navarrete9,
  11. María F González-Escribano10,
  12. Esther Vicente-Rabaneda11,
  13. Luis Rodríguez12,
  14. Carlos Tolosa13,
  15. José A Román-Ivorra14,
  16. Inmaculada Gómez-Gracia15,
  17. Francisco J García-Hernández16,
  18. Iván Castellví17,
  19. María Gallego18,
  20. Antonio Fernández-Nebro19,
  21. Rosa García-Portales20,
  22. María Victoria Egurbide21,
  23. Vicente Fonollosa3,
  24. Paloma García de la Peña22,
  25. Ana Pros23,
  26. Miguel A González-Gay24,
  27. Roger Hesselstrand25,
  28. Gabriela Riemekasten26,
  29. Torsten Witte27,
  30. Marieke J H Coenen28,
  31. Bobby P Koeleman29,
  32. Frederic Houssiau30,
  33. Vanessa Smith31,
  34. Filip de Keyser31,
  35. Rene Westhovens32,
  36. Ellen De Langhe32,
  37. Alexandre E Voskuyl33,
  38. Annemie J Schuerwegh34,
  39. Meng May Chee35,
  40. Rajan Madhok35,
  41. Paul Shiels35,
  42. Carmen Fonseca36,
  43. Christopher Denton36,
  44. Kathleen Claes37,
  45. Leonid Padykov38,
  46. Annika Nordin38,
  47. Øyvind Palm39,
  48. Benedicte A Lie40,
  49. Paolo Airó41,
  50. Raffaella Scorza4,
  51. Jacob M van Laar42,
  52. Nicolas Hunzelmann43,
  53. Alexander Kreuter44,
  54. Ariane Herrick45,
  55. Jane Worthington45,
  56. Timothy R D J Radstake2,
  57. Javier Martín1,
  58. Blanca Rueda1,10
  1. 1Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain
  2. 2Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  3. 3Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain
  4. 4Referral Center for Systemic Autoimmune Diseases, University of Milan, Milan, Italy
  5. 5Servicio de Medicina Interna, Hospital Clínico Universitario, Granada, Spain
  6. 6Servicio de Medicina Interna, Hospital Clínico de Barcelona, Barcelona, Spain
  7. 7Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain
  8. 8Servicio de Medicina Interna, Hospital Carlos-Haya, Málaga, Spain
  9. 9Servicio de Medicina Interna, Hospital Virgen de las Nieves, Granada, Spain
  10. 10Servicio de Inmunología, Hospital Virgen del Rocío, Sevilla, Spain
  11. 11Servicio de Reumatología, Hospital de la Princesa, Madrid, Spain
  12. 12Servicio de Reumatología, Hospital Clinico San Carlos, Madrid, Spain
  13. 13Servicio de Medicina Interna, Hospital Parc Tauli, Sabadell, Spain
  14. 14Servicio de Reumatología, Hospital del Doctor Peset aleixandre, Valencia, Spain
  15. 15Servicio de Reumatología, Hospital Reina Sofía, Córdoba, Spain
  16. 16Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla, Spain
  17. 17Servicio de Reumatología, Hospital de Sant Pau, Barcelona, Spain
  18. 18Servicio de Medicina Interna, Hospital Central de Asturias, Oviedo, Spain
  19. 19Servicio de Reumatología, Hospital Carlos Haya, Málaga, Spain
  20. 20Servicio de Reumatología, Hospital Virgen de la Victoria, Málaga, Spain
  21. 21Servicio de Medicina Interna, Hospital de Cruces, Barakaldo, Spain
  22. 22Servicio de Reumatología, Hospital Ramón y Cajal, Madrid, Spain
  23. 23Servicio de Reumatología, Hospital Del Mar, Barcelona, Spain
  24. 24Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander, Spain
  25. 25Department of Rheumatology, Lund University Hospital, Lund, Sweden
  26. 26Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
  27. 27Hannover Medical School, Hannover, Germany
  28. 28Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  29. 29Section Complex Genetics, Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
  30. 30Université Catholique de Louvain (UCL), Brussels, Belgium
  31. 31University of Ghent, Ghent, Belgium
  32. 32University of Leuven (KULeuven), Leuven, Belgium
  33. 33Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
  34. 34Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  35. 35University of Glasgow, Glasgow, UK
  36. 36Centre for Rheumatology, Royal Free and University College Medical School, London, UK
  37. 37Department of Genetics, University of Ghent, Ghent, Belgium
  38. 38Karolinska Institute, Stockholm, Sweden
  39. 39Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway
  40. 40Institute of Immunology, Rikshospitalet, Oslo University Hospital, Oslo, Norway
  41. 41Servizio di Reumatologia ed Immunologia Clinica Spedali Civili, Brescia, Italy
  42. 42Institute of Cellular Medicine, Newcastle University, Newcastle, UK
  43. 43Department of Dermatology, University of Cologne, Cologne, Germany
  44. 44Ruhr University of Bochum, Bochum, Germany
  45. 45Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
  1. Correspondence to Blanca Rueda, Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, Parque Tecnológico Ciencias de la Salud, Avenida del Conocimiento s/n, 18100-Armilla, Granada, Spain; blarume{at}ugr.es

Abstract

Objectives The aim of this study was to confirm the influence of TNFSF4 polymorphisms on systemic sclerosis (SSc) susceptibility and phenotypic features.

Methods A total of 8 European populations of Caucasian ancestry were included, comprising 3014 patients with SSc and 3125 healthy controls. Four genetic variants of TNFSF4 gene promoter (rs1234314, rs844644, rs844648 and rs12039904) were selected as genetic markers.

Results A pooled analysis revealed the association of rs1234314 and rs12039904 polymorphisms with SSc (OR 1.15, 95% CI 1.02 to 1.31; OR 1.18, 95% CI 1.08 to 1.29, respectively). Significant association of the four tested variants with patients with limited cutaneous SSc (lcSSc) was revealed (rs1234314 OR 1.22, 95% CI 1.07 to 1.38; rs844644 OR 0.91, 95% CI 0.83 to 0.99; rs844648 OR 1.10, 95% CI 1.01 to 1.20 and rs12039904 OR 1.20, 95% CI 1.09 to 1.33). Association of rs1234314, rs844648 and rs12039904 minor alleles with patients positive for anti-centromere antibodies (ACA) remained significant (OR 1.23, 95% CI 1.10 to 1.37; OR 1.12, 95% CI 1.01 to 1.25; OR 1.22, 95% CI 1.07 to 1.38, respectively). Haplotype analysis confirmed a protective haplotype associated with SSc, lcSSc and ACA positive subgroups (OR 0.88, 95% CI 0.82 to 0.96; OR 0.88, 95% CI 0.80 to 0.96; OR 0.86, 95% CI 0.77 to 0.97, respectively) and revealed a new risk haplotype associated with the same groups of patients (OR 1.14, 95% CI 1.03 to 1.26; OR 1.20, 95% CI 1.08 to 1.35; OR 1.23, 95% CI 1.07 to 1.42, respectively).

Conclusions The data confirm the influence of TNFSF4 polymorphisms in SSc genetic susceptibility, especially in subsets of patients positive for lcSSc and ACA.

View Full Text

Statistics from Altmetric.com

Introduction

Systemic sclerosis (SSc) is a connective tissue disorder characterised by fibrosis, vascular damage and immune imbalance. This pathology has a complex polygenic aetiology and variable clinical manifestations. Patients with SSc are commonly classified in two major subgroups: limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc).1 Autoantibody status, especially anti-centromere antibodies (ACA) and anti-topoisomerase antibodies (ATA), is clinically used as prognostic biomarker.1

Familial clustering and ethnic influences support the genetic component of this disease.2 Initially, only major histocompatibility complex (MHC) genes were firmly associated with SSc.2 Nevertheless, recently a number of candidate genes such as STAT4, BANK1 or IRF5, have been related to SSc genetic predisposition in independent populations by well powered studies.3 Hypothesis free approaches such as genome-wide association studies, have lately confirmed the role of MHC, IRF5 and STAT4 and uncovered new SSc susceptibility loci, such as CD247.4 ,5

In this line of research, four TNFSF4 promoter single nucleotide polymorphisms (SNPs) rs1234314, rs844644, rs844648 and rs12039904 were recently implicated in susceptibility to SSc in a Caucasian American population (composed of 1059 patients with SSc and 698 healthy controls).6 Interestingly, the TNFSF4 gene, which encodes OX40L, is considered as a potential autoimmunity candidate gene. OX40L is expressed on activated antigen presenting cells and endothelial cells in acute inflammation. Furthermore, it enhances B cell proliferation and differentiation,7 and its binding to OX40 (CD134) promotes proliferation and survival of T cells.8 All these processes could play an important role in loss of immune tolerance and pathology as observed in SSc.

On this basis, the aim of this study was to replicate the association of TNFSF4 gene promoter polymorphisms with SSc through a large association study in eight independent European populations of Caucasian ancestry, in order to confirm the implication of TNFSF4 gene in SSc genetic susceptibility and phenotypic features.

Patients and methods

Patients

A total of 3014 cases and 3125 controls from 8 European Caucasian cohorts (Spain, Germany, The Netherlands, Belgium, Italy, Sweden, Norway and UK) were included in this study. Patients with SSc were diagnosed accordingly with the 1980 American College of Rheumatology classification criteria for SSc,9 and were subdivided into those with lcSSc and dcSSc as defined by LeRoy et al.10

The following clinical data was collected for ascertainment of clinical phenotype of patients with SSc: age, gender, disease duration and presence of SSc specific autoantibodies, ATA and ACA. Clinical subtype information was available for 82% of the patients, and autoantibody status was available for 74% of the patients. The control population consisted of unrelated healthy individuals recruited in the same geographical regions as patients with SSc, matched by age, sex and ethnicity. The local ethical committees at all participating centres approved the study. Patients and controls were included in the study after written informed consent was obtained.

TNFSF4 polymorphisms genotyping

SNPs rs1234314, rs844644, rs844648 and rs12039904 (tag-SNP of rs2205960 SNP) were genotyped using TaqMan SNP genotyping assays in a 7900HT Real-Time PCR System from Applied Biosystems (Foster City, California, USA). The genotyping call rate was over 93% in all cases and controls included.

Statistical analysis

Association was calculated by 2×2 contingency tables and Fisher's exact test or χ2 when necessary, obtaining p values, OR and 95% CI using PLINK (V.1.06; http://pngu.mgh.harvard.edu/purcell/plink/). p Values below 0.05 after Benjamini and Hochberg False Discovery Rate Method correction were considered as statistically significant. Hardy–Weinberg equilibrium (HWE) was tested for all SNPs at significance level=0.01.

Haplotypes were constructed using PLINK (V.1.06) and Haploview V.4.2 (http://www.broadinstitute.org/haploview/haploview). Haplotypes having a frequency <5% in control groups were excluded for the analysis. Haplotype p values were corrected using Bonferroni correction. Meta-analysis was carried out by PLINK (V.1.06) and StatsDirect (V.2.6.6; StatsDirect, Altrincham, UK) in the case of haplotypes. Homogeneity among cohorts was calculated using the Breslow–Day method, and OR calculation was performed under fixed effects model (Mantel–Haenszel) or random effects (DerSimonian–Laird) when necessary.

The power of the study for the whole set of patients and controls reached over 98% (Power Calculator for Genetic Studies 200611).

Results

Analysis of TNFSF4 promoter polymorphisms

The allelic frequencies of the four SNPs tested were similar to those reported for Caucasian populations in previous studies6 ,12 ,13 and the international HapMap Project (http://hapmap.ncbi.nlm.nih.gov/). In addition, the genotypic distribution of healthy controls and SSc cases was in HWE for all SNPs.

Table 1 describes allelic distribution of the four SNPs in the pooled analysis, and supplementary tables 1–4 contain detailed data for each population. Pooled analysis of rs1234314 SNP showed statistically significant association of the G allele with SSc (p=0.03, OR 1.15, 95% CI 1.02 to 1.31), with the subset of patients with lcSSc (p=0.003, OR 1.22, 95% CI 1.07 to 1.38) and with patients positive for ACA (p=2.51E-04, OR 1.23, 95% CI 1.10 to 1.37) (table 1 and supplementary figure 1). The association of this genetic marker with lcSSc remained significant after the comparison of this subgroup of patients with those having dcSSc (p=0.01, OR 0.85, 95% CI 0.75 to 0.96, data not shown). Pooled analysis revealed a significant protective association of rs844644 minor allele with lcSSc (p=0.03, OR 0.91, 95% CI 0.83 to 0.99) (table 1, supplementary figure 2). Similarly, the rs844648 A allele showed a significant association with susceptibility to lcSSc and ACA positive subgroups (p=0.04, OR 1.10, 95% CI 1.01 to 1.20; p=0.04, OR 1.12, 95% CI 1.01 to 1.25, respectively) (table 1, supplementary figure 3). Pooled analysis revealed a strong association of rs12039904 T allele with patients with SSc (p=1.53E-04, OR 1.18, 95% CI 1.08 to 1.29), with patients in the lcSSc subgroup (p=2.81E-04, OR 1.20, 95% CI 1.09 to 1.33) and patients in the ACA-positive subgroup (p=2.09E-03, OR 1.22, 95% CI 1.07 to 1.38) (table 1, supplementary figure 4).

Table 1

Pooled analysis of TNFSF4 promoter genetic variants

TNFSF4 haplotype analysis

Haplotypes represented in over 5% of the healthy controls in any of the eight populations considered, were selected for pooled analysis (table 2 and supplementary table 5). Linkage disequilibrium patterns were tested in each of the eight cohorts analysed (supplementary table 6). Only two haplotypes reached significant association with SSc, CAGC (p=2.30E-03, OR 0.88, 95% CI 0.82 to 0.96) and GCAT (p=9.10E-03, OR 1.14, 95% CI 1.03 to 1.26) (supplementary table 5) (the order of the SNPs is rs1234314-rs844644-rs844648-rs12039904). Interestingly, the CAGC haplotype is composed by the protective alleles of all the tested SNPs while the GCAT haplotype harbours all the risk alleles. The association of CAGC and GCAT haplotypes with SSc clinical features remained significant for patients in the lcSSc (p=6.8E-03, OR 0.88, 95% CI 0.80 to 0.96; p=1.3E-03, OR 1.20, 95% CI 1.08 to 1.35, respectively, data not shown) and ACA-positive subsets (p=0.01, OR 0.86, 95% CI 0.77 to 0.97; p=3.7E-03, OR 1.23, 95% CI 1.07 to 1.42, respectively, data not shown).

Table 2

Pooled analysis of TNFSF4 haplotypes in patients with systemic sclerosis and controls

Discussion

TNFSF4 polymorphisms have been related to susceptibility for different autoimmune diseases including SSc.6 ,14 With the aim of validating the initially reported association of TNFSF4 gene in SSc, we conducted a large case-control study and a pooled analysis in eight independent European populations of Caucasian ancestry.

In accordance with the report by Gourh et al,6 our study supports the implication of TNFSF4 gene promoter polymorphisms in SSc genetic predisposition. Stratification by SSc clinical subtype or autoantibody status confirmed the significant association of the TNFSF4 variants with the patients in the lcSSc subset and ACA-positive subgroup but not with patients in the dcSSc or ATA-positive subsets. Nevertheless, the risk or protective directions in the associations were consistent with those reported by Gourh et al.6

Similarly, haplotype pooled analysis results obtained in the present study keep in with the findings from Gourh et al.6 The most represented haplotype in both reports are equivalent, appear in similar frequency and have a protective effect. Nevertheless, in our study the opposite haplotype GCAT, which could not be observed in the previous study, showed a significant risk association with SSc.

Interestingly, previous findings in systemic lupus erythematosus revealed the existence of equivalent protective and risk haplotypes to the ones reported in this study. Moreover, functional data showed that the risk haplotype produced an increased level of TNFSF4 transcript (compared to the protective haplotype), and a higher surface expression of OX40L in lymphoblastoid cell lines and peripheral blood lymphocytes after activation. This overexpression seems to be related to the destruction of the DNA binding site for the transcriptional repressor E4BP4 (with a role in the survival of early B cell progenitors).12 Thus, the TNFSF4 risk haplotype associated with SSc and producing higher levels of OX40L might be implicated in the pathogenic mechanisms of SSc, by the alteration of regulatory processes controlling B and T cell proliferation and differentiation, leading to autoantibody production and tissue damage.7 ,8 ,14,,16 Further studies are necessary to elucidate the exact molecular mechanisms by which OX40L is implicated in SSc pathogenesis and more precisely how it can lead to the development of lcSSc and ACA production.

In summary, our results confirm the implication of TNFSF4 promoter polymorphisms in SSc susceptibility, especially in patients in the lcSSc and ACA-positive subgroups. These findings together with previous genetic and functional studies suggest TNFSF4 as an interesting and consistent genetic factor for SSc and other autoimmune diseases and may open new opportunities for SSc treatment.

Acknowledgments

We thank Sofía Vargas and Sonia Rodríguez for their excellent technical assistance, and all patients and donors for their collaboration. We are also thankful to EUSTAR (The EULAR Scleroderma Trials and Research group) for the facilitation of this project.

References

View Abstract

Supplementary materials

Footnotes

  • JM and BR contributed equally to this work.

  • Funding This work was supported by grants SAF2009-11110, Junta de Andalucía, grants: CTS-4977 and CTS-180 and by RETICS Program, RD08/0075 (RIER) from Instituto de Salud Carlos III (ISCIII). BR was supported by ISCIII (Programa Sara Borrell). TRDJR was funded by the VIDI laureate from the Dutch association of research (NOW) and Dutch arthritis foundation (National Reumafonds). EDL is recipient of an Aspirant fellowship from FWO Vlaanderen (Flanders Research Foundation).

  • Ethical approval Ethical approval was obtained from the Ethics Committee in each hospital involved.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.